StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a report issued on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of FibroGen in a report on Thursday, February 20th.
Read Our Latest Stock Analysis on FGEN
FibroGen Stock Up 2.9 %
Institutional Trading of FibroGen
A number of hedge funds have recently modified their holdings of FGEN. JPMorgan Chase & Co. boosted its holdings in shares of FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of FibroGen by 80.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 441,083 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of FibroGen in the 4th quarter worth about $205,000. Finally, Two Sigma Advisers LP raised its position in shares of FibroGen by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 135,600 shares during the last quarter. Institutional investors own 72.71% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
See Also
- Five stocks we like better than FibroGen
- What does consumer price index measure?
- How to Build the Ultimate Everything ETF Portfolio
- What Are Dividend Challengers?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.